Recent advancements in ropinirole hydrochloride embedded nano-techniques in Parkinson’s treatment

Manoj Kumar Katual, Gurfateh Singh, S L Harikumar


Parkinson's Disease (PD) is effecting 7-10 million people of worldwide as the report of WHO 2014. It has proved to be 2nd most a neuro-degenerative disorder of the central nervous system (CNS). It occurs due to the death of dopamine-generating cells in the substantia-nigra, a region of the midbrain. It is characterized by tremor, rigidity, bradykinesia, dementia, depression and falls or emerges with the progression of the disease. Ropinirole HCl is a low molecular weight, highly water soluble drug. It is rapidly absorbed from the G.I.T and mean peak plasma concentrations have been achieved within 1.5 h after oral doses. The oral bioavailability of Ropinirole HCl is 50% due to extensive first pass metabolism by the liver. Its mean plasma half-life is 5–6 h. The present study tries to enlighten the prior art related to Parkinson's treatment and to prepare Ropinirole HCl loaded Nano-structured lipid carriers (NLC) that may overcome the problem of bioavailability and bypass the blood brain barrier by preparing the intra-nasal drug delivery targeted to the brain thereby decreasing the dosing frequency and increasing patient compliance.


Keywords: Parkinson's Disease, Bioavailability, NLC, Nano-technology.

Full Text:



Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938–42.

Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis 2010;37:13–25.

Barbeau A. L-Dopa therapy in Parkinson’s disease. Can Med Assoc 1969;59–68.

Belluzi JD, Domino EF, May JM. A selective dopamineD2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 1994;147-54.

Carlo Ferrari. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;489-94.

Dawson VL. Neurobiology of flies and mice. Sci 2000;631-2.

De la Fuente-Fernandez R, Calne DB. Evidence for environmental causation of Parkinson’s disease. Parkinsonism and Related Disorders, 2002;235-241.

Elisabetta Esposito, Martina Fantin, Matteo Marti, Markus Drechsler, Lydia Paccamiccio, Paolo Mariani et al. Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine. Pharm Res 2008;25(7):1521-30.

Filloux F, Townsend J. Pre- and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993;119:79–88.

Forno LS, Sternberger LA, Sternberger NH. Reaction of Lewy bodies with antibodies to phosphorylated and nonphosphorylated neurofilaments. Neurosci Lett 1986;64:253–8.

Fritsch T, K Smyth, M Wallendal, T Hyde, G Leo, D Geldmacher: Parkinson Disease: Research update and clinical management. South Med Assoc 2012;105(12):650-6.

Giasson BI, Uryu K, Trojanowski, JQ. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274,7619–22.

Gibb WR. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1998;64:345–51.

Goldman JE, Yen S-H, Chiu F-C, Lewy bodies of Parkinson’s disease contain neurofilament antigens. Sci 1983;221:1082–4.

Gorell JM. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. U.S Natl Lib Med 1998;1346-50.

Harding AJ, Stimson E, Henderson JM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. J Neurol 2002;125:2431–45.

Hartley A, Stone JM, Heron C. Complex I inhibitors induce dose dependent apoptosis in PC12 cells relevance to Parkinson’s disease. J Neurochem 1994;1987–90.

Illum L. Nasal drug delivery: possibilities, problems and solutions. J Cont Release 2003;187-98.

James W Tetrud, Zigmond MJ. A novel formulation of selegiline for the treatment of Parkinson’sdisease. J Am Acad Neurol 2004;2-6.

Janice M Beitz. Parkinson's disease: a review, Frontiers in Bioscience, 2014;S6,65-74.

Karin M Jorga, Ben-Sasson SA. The effect of tolcapone on the pharmacokinetics of benserazide. European Journal of Neurology, 1996;6(2):211-9.

Kruger R., Kuhn W, Muller T. Ala30Pro mutation in the gene encoding alpha-synucleinin Parkinson’s disease. Nat Genet 1998;18(2):106-8.

Latika Nasare, Shrikant D, Shagufta A. Nasal drug delivery system: an emerging approach for brain targeting. World J Pharm Pharm Sci 1998;3(4):539-53.

Leroy E, Boyer R, Auburger G. The ubiquitin pathway in Parkinson’s disease. Nat 1998;395(6701):451-2.

Manoj Kumar Katual., Harikumar S.L., 2016. Drug delivery to CNS; various approaches for Parkinson's disease management. Int J Recent Sci Res 2016;7(3):9148-9155.

Muhammad U Ghori. Nasal Drug Delivery Systems: An Overview. American Journal of Pharmacological Sciences, 2015;3(5):110-9.

Nishan N Bobade, Ashish K Khrobragade, Jaymin M Patel, Shrikant D, Shagufta A Khan. Design and in vitro characterization of novel phase transition systems for nasal drug delivery. World J Pharm Pharm Sci 2015;4(11):1231:51.

Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999;123-144.

Pagar Swati Appasaheb. A Review on Intranasal Drug Delivery System. Int J Pharm 2013;3(4):333-44.

Popoulos MH, Lavedan C, Leroy E. Mutation in the alpha-synucleingene identified in families with Parkinson’s disease. Sci 1997;2045-47.

Sherer TB, S Chowdhury, K Peabody. D Brooks: Overcoming obstacles in Parkinson's Disease. Int J Pharm Pharm Sci 2012;1606-11.

Sumit Sharma. Shikha Lohan, RSR Murthy. Formulation and character- ization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Development and Industrial Pharmacy, 2013;1–10.

Tsong-Long Hwang, Xiaohui Li, Yuming Sun, Xue Ding, Yaqing Pan, Qing Wang. Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J Pharm Sci 2009;98(10):3735-47.

Wright Willis A, B Evanoff, M Lian, S Criswell, B Racette. Geographic and ethnic variation in Parkinson Disease: A population-based study of US Medicare Beneficiaries. Neuroepidemiol 2010;143-51.

Zhigao Huang, Yingjie Zhai, Guangxi Zhai. Etiology of Parkinson’s disease. Canadian J Neurol Sci 2003;30:10-8.